F-star Therapeutics, Inc.
(NASDAQ : FSTX)

( )
FSTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.74%178.190.7%$1350.94m
MRKMerck & Co., Inc. 0.21%92.610.7%$1211.55m
PFEPfizer Inc. -1.20%51.680.9%$1096.02m
LLYEli Lilly & Co. 0.74%327.131.1%$1026.00m
BMYBristol-Myers Squibb Co. -1.13%75.971.0%$991.64m
ABBVAbbVie, Inc. 0.03%153.851.9%$959.73m
AZNAstraZeneca Plc -0.67%65.511.0%$470.96m
SGENSeagen Inc. -1.85%176.775.7%$326.06m
GSKGSK Plc -1.01%43.310.2%$272.45m
TPTXTurning Point Therapeutics, Inc. 0.05%75.150.0%$199.28m
HZNPHorizon Therapeutics Plc 2.38%82.765.4%$174.09m
NVSNovartis AG -0.11%84.270.2%$172.25m
MRTXMirati Therapeutics, Inc. 1.10%71.961.6%$150.81m
ALNYAlnylam Pharmaceuticals, Inc. 1.67%150.738.1%$150.31m
NVONovo Nordisk A/S -0.40%111.190.1%$148.30m

Company Profile

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.